Lexicon Pharmaceuticals (LXRX) risk factors, FY2024 10-K

Risks Related to Our Business and Industry

1. 01We depend heavily on our ability to successfully complete the ongoing research and development of our drug programs. If we fail to successfully complete and gain positive results from such research and development efforts, our business will suffer and our stock price will likely decline
2. 02Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval
3. 03Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our and our collaborators’ ability to commercialize products
4. 04The commercial success of any products that we or our collaborators may develop will depend upon the degree of market acceptance among physicians, patients, health care payers and the medical community
5. 05If we are unable to establish an effective sales force, marketing infrastructure and distribution capabilities, we will not be able to successfully commercialize any products that we or our collaborators may develop
6. 06If we or our collaborators are unable to sustain our or their sales force, marketing infrastructure and distribution capability for such products, we may not be able to generate any product revenue, may generate increased expenses and may never become profitable
7. 07If we are unable to establish adequate coverage and reimbursement from third-party payers for any products that we or our collaborators may develop, our revenues and prospects for profitability will suffer
8. 08We may not be able to manufacture products that we or our collaborators may develop in commercial quantities, which would impair our ability to commercialize such products
9. 09We and our collaborators are subject to extensive and rigorous ongoing regulation relating to any products that we or our collaborators may develop
10. 10We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition
11. 11Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may negatively affect our revenues and prospects for profitability
12. 12Our competitors may develop products that impair the value of any products that we or our collaborators may develop
13. 13The outbreak of the novel coronavirus, or COVID-19, had an adverse impact on our business operations and clinical trials and another novel coronavirus could adversely affect our business in the future
14. 14severely impacted. These and similar, and perhaps more severe, disruptions in our operations due to the emergence of a novel coronavirus could negatively impact our business, operating results and financial condition
15. 15Changes in government trade policies could disrupt our supply chain or increase the costs of our clinical and commercial supply, negatively impacting our ability to conduct our clinical and commercial operations, price our commercial product competitively and conduct clinical development in a cost effective manner

Risks Related to Our Capital Requirements and Financial Results

1. 16clinical development programs or commercialization efforts or obtain funds, if at all, by entering into financing agreements on unattractive terms
2. 17We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability
3. 18Our operating results have fluctuated and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance
4. 19We have substantial indebtedness that may limit cash flow available to invest in the ongoing needs of our business
5. 20If we do not effectively manage our affirmative and restrictive covenants under the Oxford Term Loans, our financial condition and results of operations could be adversely affected

Risks Related to Our Relationships with Third Parties

1. 21Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts
2. 22We rely on third parties to carry out our preclinical studies and clinical trials, which may harm or delay our research and development efforts

Risks Related to Our Intellectual Property

1. 23If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market
2. 24We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our planned research, development and commercialization activities. We may not prevail in any such litigation or other dispute or be able to obtain required licenses
3. 25Data breaches and cyber-attacks could compromise our intellectual property or other sensitive information and cause significant damage to our business, reputational harm and financial loss
4. 26We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers

Risks Related to Our Employees and Facilities

1. 27If we are unable to manage our business, financial condition, results of operations and prospects may be adversely affected
2. 28The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to operate and expand our operations
3. 29Our facilities are located near coastal zones, and the occurrence of a hurricane or other disaster could damage our facilities and equipment, which could harm our operations

Risks Related to Environmental and Product Liability

1. 30We have used hazardous chemicals and radioactive and biological substances in our business. Any claims relating to improper handling, storage or disposal of these substances could be time consuming and costly
2. 31Our business has a substantial risk of product liability and we face potential product liability exposure far in excess of our limited insurance coverage

Risks Related to Our Common Stock

1. 32Invus, L.P. and its affiliates own a substantial interest in our outstanding common stock and may have interests which conflict with those of our other stockholders
2. 33Invus has additional rights under its stockholders’ agreement relating to the membership of our board of directors and under our certificate of incorporation relating to preemptive and consent rights, which provide Invus with substantial influence over significant corporate matters
3. 34Our stock price may be extremely volatile
4. 35Future issuances or sales of our common stock, or the perception that such issuances or sales may occur, may depress our stock price
5. 36If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
6. 37If we are unable to meet Nasdaq continued listing requirements, including minimum trading price, Nasdaq may take action to delist our common stock